The Landscape of Cancer Vaccines and Research Platforms: The Cutting Edge

by BiopharmaTrend 

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   504    Comments 0

During this 1-day event, November 23, speakers from Deep Pharma Intelligence will share their findings from a unique market study revealing R&D platforms for developing therapeutic cancer vaccines, the key players in each category, the science behind the development, and case studies illustrating opportunities and challenges of each research strategy. 

Speakers will present categorization of the 5 platforms -- including relatively mainstream strategies -- Neoantigen Platform, Tumor-associated Antigens Platform, Cellular Platform, and Oncolytic Viruses Platform -- and the latest breakthrough and a potentially disruptive research strategy --  Antigenic Essence Platform. 

The webinar will host research and business presentations from the Deep Pharma Intelligence team and guest speaker presentations by invited industry experts.

Share this:              

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *

SHARE